idea-004 · human · wrapped
Read this before anything else on the page. A low count here is usually a
statement about this repo's tooling rather than about the idea — a
unconfirmed reimbursement claim most often means the CMS cache file
is absent and nothing was searched, which is not evidence that a code
does not exist.
The packet a human reads. See docs/wrap-spec.md. This section says nothing about whether the idea is good — it says the file is finished enough to be read, and names what to do next. Filling it in advances no candidate and approves nothing.
The one-paragraph version. A wearable light-therapy wrap for newborns with jaundice, so the baby can be treated at home instead of staying in or returning to hospital. Jaundiced newborns are treated by lying under blue light, which breaks down the bilirubin causing it; today that usually means an inpatient stay whose only purpose is holding the baby under a lamp. This is a soft wrap with LEDs built in, rented to the family by a medical-equipment supplier and worn for most of the day. Its distinguishing feature is a built-in light sensor that records how much light actually reached the skin and for how long, so the prescribing clinician can see whether the baby really got the treatment. It deliberately does not measure bilirubin — adding that would put it on a slower, more expensive regulatory route.
What would have to be true, quoted from each deck's load-bearing condition:
Cheapest next test: Restore the CMS cache files and re-run hcpcs E0202, payment E0202 and coverage E0202. The file's own Unresolved-claims analysis calls group (a) "the cheapest group to fix: one set of CMS files resolves the entire Reimbursement factor", and singles out the descriptor's photometer requirement as "the most load-bearing line in the file". Selected from that grouping and the Reimbursement row of the Scores table; this is a selection from that gap analysis, not a new judgement, and not a view about the idea. Two caveats the file states itself and this packet repeats rather than hides: the caches were populated on 2026-08-30 and this candidate was never re-run against them, so this is a scheduled pass rather than an open question; and even once run, whether "with photometer" is binding for payment is a DME-MAC payment-policy question the HCPCS file cannot settle.
Where the evidence actually stands. 3 of 49 claims verified, 46 unconfirmed, none refuted — the thinnest verified position of any wrapped candidate in this portfolio. 7 of 9 factors carry a score in the Stage 2 triage table and 3 of 4 core factors do; the remaining rows carry named gaps rather than blanks, which is what the wrap requires.
All three verified claims concern permission, and none concerns capability or demand. They are the launch classification [claim 1: verified], the predicate pool and its labels [claim 2: verified], and the classification of a measurement route the candidate is not currently taking [claim 31: verified]. A reader skimming for green ticks will mistake permission for capability.
Fourteen claims were added by the research lane since 2026-08-25 and not one moved a tag, because a literature scan can locate a paper but never appraise it. They nonetheless changed this packet substantially, in three directions a Stage 6 reader should have.
The market is better measured. US births are now a sourced figure rather than an estimate [claim 36: unconfirmed], with two US birth cohorts behind the eligible band [claim 37: unconfirmed], [claim 38: unconfirmed].
The commercial risk got sharper, not vaguer. The first real payment figure for E0202 in this file is a Louisiana Medicaid rate of $33.71 [claim 44: unconfirmed], and an implementation study of home phototherapy independently names lack of reimbursement options as one of the two main barriers to the service existing at all [claim 42: unconfirmed]. Note the structural reason the national CMS files will help less here than elsewhere in this portfolio: newborns are not Medicare beneficiaries [claim 6: unconfirmed], so the payers that decide this business are Medicaid and commercial plans, and the decisive read is a state policy a human pulls by hand.
The device risk acquired its first evidence. A first-in-human pilot of a wearable phototherapy device in 12 neonates completed treatment within 48 hours in 83%, with 2 of 12 switched to conventional intensive phototherapy because bilirubin kept rising despite wearable treatment [claim 41: unconfirmed]. That is a small study of a different device, and it is the exact failure mode the file names as this candidate's device-specific risk [claim 14: unconfirmed]. It also cuts both ways: it is the strongest argument yet for the dose record, which is how a clinician would tell "this baby needs escalation" from "this wrap is not delivering".
One competitive fact belongs in the same breath. The class now contains two cleared wrap/wearable garments from 2025-2026, BiliWrap and SnugLit, within 10 LBI clearances over ten years [claim 47: unconfirmed], and the cleared analog's indication already covers this candidate's whole target population and more, caregiver-administered, at home [claim 2: verified]. The narrowed 35-week in-band indication is therefore not a commercial differentiator, and the entire differentiation case rests on the dose record — which is unbuilt, unmeasured, and the feasibility deck's load-bearing condition. Finally, FTO is unexamined rather than clear: the claim names no patent number and no search was ever attempted [claim 28: unconfirmed], on the rubric's one automatic-kill factor, in a form factor that has just drawn two new entrants.
| Intended use | For use in the home under prescription to deliver phototherapy to newborns of at least 35 weeks gestational age with uncomplicated indirect hyperbilirubinemia whose total serum bilirubin is above the phototherapy threshold but below the escalation-of-care threshold, as an alternative to inpatient readmission for phototherapy. |
|---|---|
| Mechanism | Narrow-band ~450-475 nm LED array in a wrap/garment form factor delivering measured spectral irradiance over a large fraction of body surface area, with an onboard radiometer logging irradiance x exposure time and transmitting a dose-and-adherence record to the ordering clinician |
| Device class | # Launch route first. The second entry is the obvious product; Class II — 21 CFR 880.5700 (product code LBI, "Neonatal Phototherapy Unit") — 510(k) —; launch designation; Class II — regulation number NOT identified by the Generator — a transcutaneous; bilirubinometer / bilirubin test-system route. NOT live under the current intended_use.; Becomes live the moment the product makes any bilirubin measurement claim, which is; the natural next feature and a separate review. Carried so that the extension is a; visible regulatory decision rather than a surprise. |
| Predicate or analog | LBI / 21 CFR 880.5700 pool. Generator identified by name, via web search; only: neoBLUE (Natus), BiliWrap Phototherapy System, and SnugLit; Wearable Phototherapy System (K251308, cleared 2025) — the last of which; is itself a wearable form factor and is the closest analog, not a; differentiator. Fiberoptic phototherapy blankets (BiliBlanket lineage); are the incumbent home form factor. |
| Launch jurisdiction | US |
| Target | human |
| Factor | Score | What would settle it |
|---|---|---|
| Regulatory pathway | 4 | classification --product-code LBI and regulation 880.5700 for class and pathway; clearances --product-code LBI --since 5y for the predicate pool; the K251308 510(k) summary and its indications-for-use statement read directly, to…the rest of this gap analysisconfirm the wearable analog's indication actually overlaps this one rather than merely sharing a product code; CFR text of 880.5700 for special controls. |
| Reimbursement pathway | 3 | hcpcs E0202 for the primary descriptor (settles the load-bearing photometer-in-descriptor claim); payment E0202 for the DMEPOS fee-schedule allowable — read as a benchmark, not as the answer for this population; coverage E0202…the rest of this gap analysisfor any Medicare policy, expected to be thin or absent. The decisive sources are Tier 3 human attachments no connector reaches: two or three state Medicaid DME fee schedules and home-phototherapy coverage criteria (e.g. CA Medi-Cal, TX, NY) and at least one named commercial payer DME medical policy for home phototherapy (e.g. an Aetna CPB or Cigna coverage policy), plus whether prior authorization is required. |
| TAM | 3 | Births: NCHS/CDC WONDER natality final birth data, not a secondary citation. Phototherapy incidence at 35+ weeks: the 2022 AAP clinical practice guideline plus a named published birth-cohort study (Kaiser Permanente NCC / Northern…the rest of this gap analysisCalifornia cohort is the usual primary) —literature can locate them; the guideline also settles the threshold-direction claim. Home-eligible share: no public source is likely to exist — expect a licensed report or payer-claims analysis a human must attach, or derive it from a Medicaid claims extract. Revenue per episode: falls out of payment E0202 plus typical episode length from the AAP guideline. Note: the procedures connector is useless for this factor — it is Medicare volume, and this population has no Medicare exposure at all. |
| FTO / IP | — | A patents search on the actual mechanism claims — wearable/garment-form phototherapy enclosures, and specifically onboard radiometric dosimetry logging irradiance x exposure time tied to a treatment record, which is the novel element…the rest of this gap analysisand therefore the likely blocking-art surface. Start from assignees named in the file (Natus, GE, and the SnugLit K251308 sponsor) and from the BiliBlanket fiberoptic lineage; check expiration dates on anything live. A Tier 3 legal FTO opinion is the eventual settling source, but a connector-level landscape read is enough to score the factor. |
| Moat / defensibility | 2 | Not connector-checkable as written, and the file says so. What would convert it: (a) the patents landscape above — a defensible position on dosimetry logging is the only hard moat available; (b) any **payer policy or LCD/Medicaid…the rest of this gap analysiscriterion that requires documented delivered irradiance or adherence** for payment, which would turn the dosimetry record from a feature into a condition of billing; (c) the primary HCPCS E0202 descriptor, since if "with photometer" is genuinely binding it raises the floor for every commodity entrant. Item (b) is a human-attached payer-policy read. |
| Mechanism & clinical risk | 4 | The 2022 AAP guideline's irradiance specification (the ~30 uW/cm2/nm-at-the-skin target and body-surface-area guidance) as the dose target to design against; IEC 60601-2-50 (particular requirements for infant phototherapy…the rest of this gap analysisequipment) and the 880.5700 special controls for the photometric bench-test protocol and radiometer accuracy tolerance;literature for published home-vs-inpatient phototherapy efficacy comparisons and for under-dosing/treatment-failure rates in home fiberoptic use; recalls --product-code LBI for the historical failure modes of this device class. |
| Capital intensity & time-to-revenue | 3 | Benchmark the regulatory leg against actual LBI submissions: clearances --product-code LBI --since 5y for decision dates, then read two or three 510(k) summaries for whether clinical data was required or bench photometric testing…the rest of this gap analysissufficed; FDA's published average 510(k) decision time for 880.5700 / Class II for the calendar estimate. For the commercial leg the settling sources are non-connector: a DME operator's unit economics (fleet cost per unit, utilisation, delivery cost per episode, days-to-payment) — either a licensed industry report or an operator interview a human must supply. Prior-auth turnaround comes from the same payer policies named under Reimbursement. |
| Competitive intensity | 2 | clearances --product-code LBI --since 5y for who has actually entered and when, and recalls --product-code LBI for incumbent trouble; the K251308 clearance record for the wearable entrant's real indication and claimed features.…the rest of this gap analysisFunding, launch and commercial-traction data has no connector — a licensed source (PitchBook/Crunchbase/CB Insights) or a human-attached market scan is required, as is any read on which DME suppliers hold the home-phototherapy rental relationships regionally. |
| Strategic fit & portfolio balance | — | A human-supplied portfolio thesis / capital-allocation stance (Tier 3) — hero-bet vs. cash-generative-spoke targets, appetite for service-heavy DME operations, and whether an existing DME or neonatal-channel relationship is available…the rest of this gap analysisto leverage. Nothing an agent can look up; this factor stays blank until that is written down. |
All six wrap criteria are met.
Domain dossier: neonatal-hyperbilirubinemia-home-phototherapy
Source file: knowledge-base/candidates/idea-004.md
Nothing on this page is a recommendation. Shortlist review, legal and clinical sign-off and capital allocation are human-only decisions, and no agent in this repo may make or simulate one. This is a compilation of what the candidate file says.